uniQure N.V. (QURE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31..
Quick ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 59.20M USD | Liabilities, Current |
| Cash and equivalents | 139.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 3.56M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $59.20M | $139.99M | (m) | $3.56M | (m) | (m) |
| 2025-12-31 | (m) | $62.92M | $80.24M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $100.63M | $597.06M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $40.93M | $253.78M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $36.31M | $217.23M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $40.05M | $158.93M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $71.27M | $251.63M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $80.47M | $287.88M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $63.47M | $243.06M | (m) | (m) | $7.67M | (m) |
| 2023-12-31 | (m) | $73.67M | $241.36M | (m) | (m) | $12.02M | (m) |
| 2023-09-30 | (m) | $68.61M | $229.48M | (m) | (m) | $15.65M | (m) |
| 2023-06-30 | (m) | $68.36M | $513.60M | (m) | (m) | $10.21M | (m) |
| 2023-03-31 | (m) | $66.34M | $153.85M | (m) | (m) | $7.48M | (m) |
| 2022-12-31 | (m) | $75.92M | $228.01M | (m) | (m) | $6.92M | (m) |
| 2022-09-30 | (m) | $63.97M | $440.31M | (m) | (m) | $4.08M | (m) |
| 2022-06-30 | (m) | $48.26M | $500.52M | (m) | (m) | $2.95M | (m) |
| 2022-03-31 | (m) | $44.70M | $524.89M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $36.76M | $556.26M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $41.92M | $578.46M | (m) | $3.77M | (m) | (m) |
| 2021-06-30 | (m) | $46.09M | $677.33M | (m) | $2.71M | (m) | (m) |
| 2021-03-31 | (m) | $32.10M | $260.81M | (m) | $5.45M | (m) | (m) |
| 2020-12-31 | (m) | $27.33M | $244.93M | (m) | $6.62M | (m) | (m) |
| 2020-09-30 | (m) | $33.35M | $279.49M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $29.84M | $314.26M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $27.13M | $342.03M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $31.63M | $377.79M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $28.45M | $403.16M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $23.37M | $184.09M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $22.42M | $208.79M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $19.97M | $234.90M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $32.01M | $239.55M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $31.44M | $259.18M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $26.56M | $140.82M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $19.23M | $159.37M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $25.37M | $88.93M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $23.13M | $104.09M | (m) | $4.19M | (m) | (m) |
| 2017-03-31 | (m) | $20.47M | $120.27M | (m) | $1.23M | (m) | (m) |
| 2016-12-31 | (m) | $22.72M | $132.50M | (m) | $3.68M | (m) | (m) |
| 2016-09-30 | (m) | (m) | $157.55M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | $183.93M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | $209.68M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $26.91M | $221.63M | (m) | (m) | $474.00K | (m) |
| 2014-12-31 | (m) | (m) | $64.69M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $32.78M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |